Lakewood-Amedex Biotherapeutics Inc. (NASDAQ:LABT – Get Free Report) saw a large growth in short interest in October. As of October 30th, there was short interest totaling 152,917 shares, a growth of 69.8% from the October 15th total of 90,040 shares. Approximately 6.8% of the company’s shares are short sold. Based on an average trading volume of 6,760,367 shares, the days-to-cover ratio is presently 0.0 days.
Wall Street Analysts Forecast Growth
Several equities research analysts have recently commented on LABT shares. Wall Street Zen downgraded Lakewood-Amedex Biotherapeutics from a “sell” rating to a “strong sell” rating in a report on Saturday, November 7th. HC Wainwright started coverage on Lakewood-Amedex Biotherapeutics in a report on Wednesday, October 28th. They issued a “buy” rating on the stock. Finally, Weiss Ratings raised shares of Lakewood-Amedex Biotherapeutics from a “sell (e-)” rating to a “sell (e)” rating in a research report on Friday, October 2nd. One equities research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock has an average rating of “Hold”.
Read Our Latest Report on LABT
Lakewood-Amedex Biotherapeutics Price Performance
Shares of Lakewood-Amedex Biotherapeutics stock traded down $0.06 on Monday, hitting $0.22. The company had a trading volume of 789,942 shares, compared to its average volume of 7,484,873. Lakewood-Amedex Biotherapeutics has a 1 year low of $0.17 and a 1 year high of $98.20. The stock’s 50 day simple moving average is $0.99. The firm has a market capitalization of $519,978.00 and a PE ratio of -0.05.
Lakewood-Amedex Biotherapeutics (NASDAQ:LABT – Get Free Report) last announced its quarterly earnings results on Friday, August 14th. The company reported ($2.75) earnings per share (EPS) for the quarter. As a group, analysts anticipate that Lakewood-Amedex Biotherapeutics will post 4.96 EPS for the current year.
About Lakewood-Amedex Biotherapeutics
Lakewood-Amedex Biotherapeutics is a biotechnology company focused on developing treatments for bacterial infections, including infections caused by drug-resistant pathogens. Its research centers on bisphosphocins, a class of investigational antimicrobial compounds. The company’s activities are primarily research and development; its investigational compounds should not be confused with approved medicines or commercially available products. Publicly available information about its specific product pipeline, operating geographies and leadership is limited.
See Also
- Five stocks we like better than Lakewood-Amedex Biotherapeutics
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
- Modine Manufacturing Scales Up to Solve the AI Heat Problem
- Nebius Revenue Is Surging, But Its Spending Is Raising Bigger Questions
Receive News & Ratings for Lakewood-Amedex Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lakewood-Amedex Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
